(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
“We are proud to be included in the widely – 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight ...
Results that may be inaccessible to you are currently showing.